Moleculin Biotech Management
Management criteria checks 3/4
Moleculin Biotech's CEO is Wally Klemp, appointed in Jul 2015, has a tenure of 8.92 years. total yearly compensation is $1.41M, comprised of 39.9% salary and 60.1% bonuses, including company stock and options. directly owns 1.96% of the company’s shares, worth €166.58K. The average tenure of the management team and the board of directors is 6.9 years and 6.9 years respectively.
Key information
Wally Klemp
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 39.9% |
| CEO tenure | 8.9yrs |
| CEO ownership | 2.0% |
| Management average tenure | 6.9yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$27m |
| Dec 31 2023 | US$1m | US$565k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$2m | US$565k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$21m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$2m | US$538k | -US$16m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$15m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$2m | US$500k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$2m | US$625k | -US$13m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$1m | US$403k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$12m |
| Jun 30 2018 | n/a | n/a | -US$13m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$1m | US$325k | -US$10m |
Compensation vs Market: Wally's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD408.13K).
Compensation vs Earnings: Wally's compensation has been consistent with company performance over the past year.
CEO
Wally Klemp (64 yo)
8.9yrs
Tenure
US$1,414,599
Compensation
Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He is President, Chief Executive Officer and Director of Zeno Corporation...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.9yrs | US$1.41m | 1.96% € 166.6k | |
| Executive VP & CFO | 7.8yrs | US$840.64k | 0.23% € 19.7k | |
| Chief Scientific Officer | 6.8yrs | US$599.11k | 0.26% € 22.0k | |
| Co-Founder | no data | no data | no data | |
| Senior Chief Medical Officer | 2.7yrs | no data | no data | |
| Chief Medical Officer of New Products | 6.6yrs | no data | no data | |
| European Chief Medical Officer | 2.1yrs | no data | no data | |
| Consultant | 6.9yrs | US$69.23k | no data | |
| Independent Advisor | no data | US$118.49k | no data |
6.9yrs
Average Tenure
69yo
Average Age
Experienced Management: MOL's management team is seasoned and experienced (6.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.9yrs | US$1.41m | 1.96% € 166.6k | |
| Co-Founder | no data | no data | no data | |
| Independent Director | 8yrs | US$68.52k | 0% € 0 | |
| Lead Independent Director | 6.9yrs | US$81.05k | 0% € 0 | |
| Independent Director | 3.7yrs | US$63.52k | 0% € 0 | |
| Member of Annamycin Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 8yrs | US$74.90k | 0.042% € 3.6k | |
| Independent Director | 2.3yrs | US$47.15k | 0% € 0 |
6.9yrs
Average Tenure
65yo
Average Age
Experienced Board: MOL's board of directors are considered experienced (6.9 years average tenure).